Please assess the completion status of the following clinical trial:

Trial Title: High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age less than 18 years~* Crohn's disease predominantly involving the ileum and/or cecum. The diagnosis must have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3 modalities) with at least one confirmatory test having been performed no more than 36 months before entry. The diagnosis must have been confirmed by at least one gastroenterologist.~* Harvey Bradshaw Index of at least 7~* The onset of the acute flare should have been abrupt, declaring itself over 72 hours, and should have started no more than 4 weeks before study entry. Symptoms relating to the flare should not have diminished or started to improve prior to entry.~* Written informed consent~Exclusion Criteria:~* Concomitant corticosteroids, budesonide~* Corticosteroids within 2 months~* Cyclosporine, mycophenolate mofetil or experimental drugs during the last three months~* Maintenance infliximab, or infliximab or other biologics in the preceding 3 months~* If the severity of the flare has started to decrease spontaneously~* Coexisting diagnosis of primary sclerosing cholangitis~* Infectious diarrhea~* Signs of intestinal obstruction or perforation~* New fistulization as part of the acute flare or increased activity in chronic fistula(e) as part of the acute flare~* Hypersensitivity to 4-ASA or any components of PASER®~* Pregnancy or breast-feeding~* Failure of a woman of child-bearing potential to agree to use adequate contraception for the 4 week period of the trial, if sexually active~* Severe renal or hepatic disease (i.e., more than 3 times upper limit of normal) or a WBC \< 3,000 during the preceding three months

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): 4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).